<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial management of hypertensive emergencies and urgencies in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial management of hypertensive emergencies and urgencies in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial management of hypertensive emergencies and urgencies in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph T Flynn, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George A Woodward, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic discusses the initial management of hypertensive emergencies and urgencies in children. The diagnostic evaluation of acute severe hypertension in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Acute severe hypertension has traditionally been divided into hypertensive emergencies and hypertensive urgencies. However, any classification scheme that divides the clinical presentation of patients with acute severe hypertension into separate categories is by nature arbitrary [<a href="#rid1">1,2</a>]. Clinical judgment must be used to gauge the severity of hypertension and guide management.</p><p>While there is no specific numerical value or blood pressure (BP) percentile that identifies "acute severe hypertension" in children and adolescents, in one relatively large case series of pediatric patients with severe hypertension, most patients had BP readings well in excess of stage 2 hypertension  (<a class="graphic graphic_table graphicRef114574" href="/z/d/graphic/114574.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. The 2017 American Academy of Pediatrics Clinical Practice Guideline on childhood hypertension suggests that clinicians become concerned about acute target-organ damage when the patient's BP exceeds 30 mmHg above the 95<sup>th</sup> percentile for sex, age, and height  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/z/d/graphic/62371.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">table 3</a>) [<a href="#rid4">4</a>].</p><p>The classification of BP in infants, children, and adolescents is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents", section on 'Definitions'</a> and  <a class="medical medical_review" href="/z/d/html/16151.html" rel="external">"Evaluation and diagnosis of hypertension in infants between one month and one year of age", section on 'Normal blood pressure'</a> and  <a class="medical medical_review" href="/z/d/html/5001.html" rel="external">"Etiology, clinical features, and diagnosis of neonatal hypertension", section on 'Normal blood pressure'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Hypertensive emergency</span><span class="headingEndMark"> — </span>An acute severe symptomatic elevation in BP <strong>with</strong> evidence of potentially life-threatening symptoms or target-organ damage (eg, hypertensive encephalopathy, heart failure, or acute kidney injury) defines a hypertensive emergency [<a href="#rid5">5-7</a>]. BPs are commonly elevated far above the level of stage 2 hypertension  (<a class="graphic graphic_table graphicRef114574" href="/z/d/graphic/114574.html" rel="external">table 1</a>). Patients with a hypertensive emergency warrant rapid assessment to exclude conditions that might alter BP management followed by emergency administration of intravenous (IV) antihypertensive agents to rapidly lower BP  (<a class="graphic graphic_algorithm graphicRef119591" href="/z/d/graphic/119591.html" rel="external">algorithm 1</a>).</p><p>The presence or absence of symptoms or target organ damage is more important than the absolute BP level. For example, a child with chronic hypertension may have impressively high BP measurements without symptoms. Another child with an acute rise in BP may manifest a hypertensive emergency despite a BP that seems to be only moderately elevated.</p><p class="headingAnchor" id="H6"><span class="h2">Hypertensive urgency</span><span class="headingEndMark"> — </span>An acute severe elevation in BP <strong>without</strong> life-threatening symptoms or evidence of acute target-organ damage describes a hypertensive urgency [<a href="#rid5">5-7</a>]. A child with hypertensive urgency warrants a prompt evaluation. The duration of hypertension (acute or chronic) is an important determinant of intervention  (<a class="graphic graphic_algorithm graphicRef119592" href="/z/d/graphic/119592.html" rel="external">algorithm 2</a>). (See <a class="local">'Hypertensive urgency'</a> below.)</p><p class="headingAnchor" id="H2144384458"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of children with hypertensive emergencies, which includes the recognition of signs of target-organ damage and identification of underlying conditions that alter blood pressure (BP) management, is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The initial management is determined by the presence of a hypertensive emergency with life-threatening symptoms or target-organ damage  (<a class="graphic graphic_algorithm graphicRef119591" href="/z/d/graphic/119591.html" rel="external">algorithm 1</a>) or a hypertensive urgency  (<a class="graphic graphic_algorithm graphicRef119592" href="/z/d/graphic/119592.html" rel="external">algorithm 2</a>) [<a href="#rid1">1,2,6-11</a>]. Knowledge of the most prevalent etiologies by age group also helps to guide treatment decisions  (<a class="graphic graphic_table graphicRef73225" href="/z/d/graphic/73225.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children"</a> and <a class="local">'Conditions that alter initial treatment'</a> below.)</p><p class="headingAnchor" id="H871192404"><span class="h2">Initial stabilization</span><span class="headingEndMark"> — </span>While the presence of severe hypertension is being confirmed, the patient should be placed in a treatment area that can support critical care functions and monitoring. Treatment includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Establish continuous cardiorespiratory monitoring, including pulse oximetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Support the airway and breathing as needed while confirming and monitoring the BP. Medications that might increase BP (eg, <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">ketamine</a>) should be avoided during rapid sequence intubation. (See  <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hypertensive emergencies (acute severe symptomatic elevation in BP <strong>with</strong> evidence of potentially life-threatening symptoms or target-organ damage), establish intravenous (IV) access consisting of two IV lines, whenever possible. One IV line should be dedicated to administration of antihypertensive medications. Initial laboratory studies should be obtained, if not already available  (<a class="graphic graphic_table graphicRef57292" href="/z/d/graphic/57292.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Ancillary studies'</a>.)</p><p></p><p class="bulletIndent1">Measure BP frequently: either automated/oscillometric or ausculatory BP measurements every one to two minutes or, if possible, intra-arterial BP measurement. However, treatment should <strong>not</strong> be delayed to obtain arterial cannulation. Frequently repeated BP measurement by means of auscultation or an automatic oscillometric BP device may suffice during initial care, with invasive monitoring established later. (See <a class="local">'Confirmation of severe hypertension'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures, if present, should be treated with anticonvulsants such as <a class="drug drug_pediatric" data-topicid="12565" href="/z/d/drug information/12565.html" rel="external">lorazepam</a> (initial dose: 0.05 to 0.1 mg/kg) until seizures stop. (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with papilledema, altered mental status, seizures, or neurologic deficits on physical examination should undergo emergency neuroimaging.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Confirmation of severe hypertension</span><span class="headingEndMark"> — </span>Once severe hypertension is discovered, the BP should be confirmed with an appropriate cuff, preferably using auscultation. Too small of a cuff will artificially elevate the BP reading  (<a class="graphic graphic_figure graphicRef73414" href="/z/d/graphic/73414.html" rel="external">figure 2</a>). Patients who newly present with acute hypertension should also have BP taken in both arms and at least one leg; a lower extremity BP that is less than upper extremity BP suggests coarctation of the aorta. If manual BP measurement is not possible in the emergency situation, automated BP readings may be substituted; the same guidance regarding cuff size should be followed. (See  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents", section on 'Technique of blood pressure measurement'</a>.)</p><p>If repeated measurements confirm the BP elevation, a focused history and physical examination should be performed to identify evidence of end-organ damage (eg, hypertensive encephalopathy, heart failure, or renal disease). An acute severe elevation in BP <strong>with</strong> life-threatening symptoms (eg, respiratory distress, altered mental status, or seizures) or evidence of acute target-organ damage defines a hypertensive emergency and, after exclusion of conditions that alter initial BP management, warrants emergency lowering of BP using IV therapy. (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Identify conditions that alter initial blood pressure management'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Hypertensive emergency</span></p><p class="headingAnchor" id="H1690100117"><span class="h3">Blood pressure goal</span><span class="headingEndMark"> — </span>The ultimate goal for treatment is achievement of a systolic BP value that will promote resolution of life-threatening signs and symptoms and prevent further hypertensive target-organ damage. Generally speaking, this is typically a systolic BP at the 95<sup>th</sup> percentile for age, sex, and height  (<a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">table 3</a>) for children less than 13 years of age and BP &lt;130/80 for adolescents, but the goal should be individualized for each patient as determined by response to treatment and, if known, the underlying cause. Whenever possible, obtain emergency consultation with a physician who has expertise in managing severe pediatric hypertension.</p><p>For children with a hypertensive emergency, we suggest IV medication that, over the first eight hours of treatment, lowers systolic BP in a controlled fashion by no more than 25 percent of the difference between the current systolic BP and the goal systolic BP [<a href="#rid1">1,4</a>]. This approach is based upon expert opinion and experience. Overly rapid lowering of BP by more than 25 percent of the planned BP reduction in the first eight hours of treatment in patients with chronic hypertension can cause irreversible target-organ damage, including permanent neurologic sequelae, visual defects, myocardial infarction, and renal insufficiency due to autoregulatory responses in key circulatory beds such as the brain and kidneys [<a href="#rid2">2,7,9,12</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Initial treatment</span><span class="headingEndMark"> — </span>These treatment recommendations for hypertensive emergencies are based upon limited pediatric evidence from small observational studies and have been largely extrapolated from randomized controlled trials in adults  (<a class="graphic graphic_algorithm graphicRef119591" href="/z/d/graphic/119591.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. Prior to treatment, it is necessary to identify conditions (eg, acute intracranial injury, intracranial mass lesion, uncorrected coarctation of the aorta, preeclampsia/eclampsia, severe pain, or sympathetic overactivity) for which antihypertensive treatment is contraindicated or may need modification. (See <a class="local">'Conditions that alter initial treatment'</a> below.)</p><p>Whenever possible, an experienced clinician such as a pediatric nephrologist or intensivist should guide therapy of pediatric hypertensive emergencies once emergency stabilization is accomplished. For children with hypertensive emergencies, we suggest IV <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> rather than either <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>  (<a class="graphic graphic_table graphicRef80380" href="/z/d/graphic/80380.html" rel="external">table 6</a>). Nicardipine is the preferred medication for the treatment of severe symptomatic hypertension in infants younger than one year of age, although labetalol is also widely used (see  <a class="medical medical_review" href="/z/d/html/16308.html" rel="external">"Management of hypertension in neonates and infants", section on 'Severe symptomatic hypertension'</a>). Labetalol may cause bronchoconstriction and may need to be avoided in infants with chronic lung disease or children with asthma. Labetalol may also worsen pulmonary edema in children with heart failure.</p><p>Both <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> and <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> permit the rapid modification of treatment based upon patient response [<a href="#rid1">1,2,8,11,13,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">Labetalol</a> is given as an initial bolus followed by a continuous IV infusion (preferred) or as repeated bolus doses every 10 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">Nicardipine</a> is given as a continuous IV infusion. Bolus doses of 30 mcg/kg (up to 2 mg) of nicardipine, although not studied in children, are effective in adults and may be utilized in consultation with a pediatric nephrologist.</p><p></p><p>There is a wide range of dosing for continuous IV infusion of <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>. In general, the clinician should start with the lowest dose of the range and adjust the infusion rate based upon BP response. Within the first eight hours of treatment, infusion rates should be titrated to achieve the desired BP reduction of no more than 25 percent of the total planned systolic BP reduction (difference between the current systolic BP and the goal systolic BP) while avoiding additional symptomatic BP increases. (See <a class="local">'Blood pressure goal'</a> above.)</p><p><a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">Hydralazine</a> and sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a> have adverse effects that make them less suitable for the initial treatment of severe hypertension in children:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">Hydralazine</a> is a direct vasodilator of arterial smooth muscle. Its onset of action is slower than <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> or <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a>, and its duration of action is longer than either of these agents. Overshoot hypotension with the potential for target-organ ischemia is also more likely with hydralazine [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>, previously a commonly used agent for acute severe hypertension, is less favored because of the potential for cyanide toxicity. Approximately one-fourth of children in a clinical trial of nitroprusside had elevated cyanide levels [<a href="#rid1">1,16,17</a>]. Impaired kidney function can increase the degree of cyanide accumulation [<a href="#rid18">18</a>]. Co-administration of thiosulfate can help mitigate cyanide toxicity in patients receiving sodium nitroprusside.</p><p></p><p>In addition to antihypertensive therapy, patients with underlying chronic kidney disease and volume overload may also warrant diuretic therapy (eg, IV <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a> or <a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">bumetanide</a>) as part of the approach to their hypertension, but diuretics should never be used alone in such patients. Acute diuretic therapy may also be indicated in patients with hypertensive emergencies associated with congestive heart failure and pulmonary edema. (See  <a class="medical medical_review" href="/z/d/html/14520.html" rel="external">"Heart failure in children: Management", section on 'Diuretics'</a>.)</p><p>There is an urgent need for better information on pharmacologic management of severe hypertension in children, especially for some of the more commonly used IV antihypertensive medications, including <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> and <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a>. The lack of dosing recommendations based upon properly conducted pediatric clinical trials clearly hinders provision of safe, effective care to this vulnerable patient population.</p><p class="headingAnchor" id="H2177298563"><span class="h3">Failure to respond to initial therapy</span><span class="headingEndMark"> — </span>If initial therapy with continuous IV infusion of <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> fails to reduce the BP within 30 minutes, then we suggest escalation of therapy to continuous infusions of <strong>both</strong> labetalol (if not contraindicated) and nicardipine  (<a class="graphic graphic_table graphicRef80380" href="/z/d/graphic/80380.html" rel="external">table 6</a>).</p><p>If the patient has contraindications to <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> or if BP is not lowered after a second 30 minutes of treatment with continuous infusions of both labetalol and <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>, then, for patients with no chronic kidney disease, continuous infusion of sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a> is preferable to <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> because of its more rapid onset and shorter duration of action. To avoid excessive blood cyanide accumulation, patients with chronic kidney disease should be treated with hydralazine rather than sodium nitroprusside.</p><p>For patients receiving sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>, monitoring of cyanide levels is performed and, whenever available, prophylactic administration of thiosulfate is warranted; dose and duration of sodium nitroprusside should also be limited. Patients unresponsive to <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a>, <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>, and sodium nitroprusside may receive <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a>.</p><p>Other generally available IV medications that may be used for the management of hypertensive emergencies include <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">esmolol</a> and <a class="drug drug_pediatric" data-topicid="15983" href="/z/d/drug information/15983.html" rel="external">fenoldopam</a>. Esmolol has a rapid onset and offset of action, which can be useful in certain patient populations, such as following cardiac surgery. Fenoldopam has not proven to be as potent as other IV antihypertensive medications and is more expensive than alternative agents. There has been interest in the ultra-short-acting IV calcium channel blocker <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">clevidipine</a> [<a href="#rid19">19,20</a>], but no controlled studies have been conducted in children. It is also more expensive than other established agents such as <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> or esmolol.</p><p>When diuretic therapy is ineffective for correcting fluid overload, dialysis is indicated. (See  <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">"Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy"</a>.)</p><p>We recommend <strong>avoiding</strong> the IV angiotensin-converting enzyme inhibitor <a class="drug drug_pediatric" data-topicid="83324" href="/z/d/drug information/83324.html" rel="external">enalaprilat</a> given the lack of established pediatric dosing and known tendency to cause acute kidney injury.</p><p class="headingAnchor" id="H459382623"><span class="h2">Hypertensive urgency</span><span class="headingEndMark"> — </span>After initial stabilization and the exclusion of conditions that may alter initial BP therapy, the treatment goal for children with hypertensive urgencies depends upon the clinical situation. As in any hypertensive child, the ultimate goal would be a systolic BP &lt;90<sup>th</sup> percentile for age, sex, and height in children &lt;13 years of age or &lt;130/80 in adolescents ≥13 years of age  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/z/d/graphic/62371.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">table 3</a>). However, a higher goal such as the 95<sup>th</sup> percentile for age, sex, and height may be appropriate initially, especially if the child was not previously known to be hypertensive and was still undergoing diagnostic evaluation. (See  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Target blood pressure goals'</a>.)</p><p>Children newly presenting with a hypertensive urgency warrant careful evaluation to determine the underlying etiology, if any, and whether the hypertension is chronic or acute  (<a class="graphic graphic_algorithm graphicRef119592" href="/z/d/graphic/119592.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute onset</strong> – When the urgency arises from an acute process with a rapid change in mean arterial pressure (eg, acute glomerulonephritis), intervention should occur promptly (ie, within hours). For these children, we suggest IV bolus doses of <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> (preferred) or, for infants younger than one year of age or for children with asthma, bolus IV doses of <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>  (<a class="graphic graphic_table graphicRef80380" href="/z/d/graphic/80380.html" rel="external">table 6</a>). IV antihypertensive therapy may also be used if the patient is unable to take medications orally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic condition</strong> – For children with chronic hypertension due to a known condition (eg, chronic kidney disease) in which BP has increased gradually over time, lowering of the BP should occur less quickly (eg, over one to two days or more).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are able to take oral medication, we suggest oral <a class="drug drug_pediatric" data-topicid="12890" href="/z/d/drug information/12890.html" rel="external">isradipine</a> or <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>  (<a class="graphic graphic_table graphicRef57259" href="/z/d/graphic/57259.html" rel="external">table 7</a>). Isradipine can be compounded into a stable liquid formulation for administration to infants and toddlers. If isradipine or clonidine are not available, other potential agents include oral <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> and <a class="drug drug_pediatric" data-topicid="12615" href="/z/d/drug information/12615.html" rel="external">minoxidil</a> [<a href="#rid21">21-24</a>]. However, dosing of these agents is more difficult given the lack of stable suspension preparations.</p><p></p><p class="bulletIndent2">Short-acting oral <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">nifedipine</a> is <strong>not</strong> recommended in children due to difficulties with dosing, prolonged and unpredictable action, risk of hypotension, and rebound hypertension [<a href="#rid25">25</a>]. The onset of action for other calcium channel blockers is too slow to recommend them for children with hypertensive urgencies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient cannot take oral medications, then bolus doses of IV medications (<a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> [preferred], or, for infants younger than one year of age or for children with asthma, bolus IV doses of <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>) should be given to slowly lower the BP.</p><p></p><p class="headingAnchor" id="H17"><span class="h1">FURTHER MANAGEMENT</span><span class="headingEndMark"> — </span>Once initial control of severe hypertension is achieved, plans should be made for further diagnostic evaluation and correction of any identifiable underlying cause in consultation with the appropriate pediatric subspecialist. (See  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a>.)</p><p>The amount of time needed for further blood pressure (BP) reduction after the initial eight hours of therapy will depend upon patient factors, including presumed duration of acute severe hypertension, required regimen to control BP, and underlying etiology; and should also be guided by an experienced clinician such as a pediatric nephrologist or intensivist. (See <a class="local">'Initial treatment'</a> above and <a class="local">'Conditions that alter initial treatment'</a> below.)</p><p>If an intravenous (IV) infusion was required to control the child's BP, gradual conversion to oral antihypertensive medications under the guidance of a specialist with expertise in treating pediatric hypertension, whenever possible, should be undertaken until definitive treatment can be arranged.</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary hypertension – If the underlying cause cannot be corrected so that hypertension is abolished, or if hypertension persists after treatment, chronic pharmacologic therapy should be continued. The regimen depends upon the underlying cause of hypertension, physician comfort, and the presence of any comorbid conditions (eg, diabetes mellitus and/or kidney disease). (See  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Choice of drug'</a>.)</p><p></p><p class="bulletIndent1">Nonpharmacologic measures (eg, salt restriction and weight control) should also be utilized in conjunction with antihypertensive medications in such patients. (See  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Management approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypertension – The patient with primary hypertension as the etiology of their acute severe hypertension should also receive both nonpharmacologic and pharmacologic therapy. Nonpharmacologic measures, if successfully adhered to by the patient, offer the possibility of eventual discontinuation of drug therapy, especially if obesity is a significant contributor to the BP elevation. (See  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Management approach'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">CONDITIONS THAT ALTER INITIAL TREATMENT</span></p><p class="headingAnchor" id="H306137088"><span class="h2">Intracranial hypertension</span><span class="headingEndMark"> — </span>Blood pressure (BP) reduction is contraindicated in patients with intracranial hypertension, including children with serious intracranial injury, space-occupying brain lesions, or stroke. If a central nervous system condition is suspected or cannot be excluded based upon clinical findings, then emergency neuroimaging should be obtained prior to antihypertensive therapy. Treatment of elevated intracranial pressure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/106112.html" rel="external">"Elevated intracranial pressure (ICP) in children: Management"</a>.)</p><p class="headingAnchor" id="H2248758279"><span class="h2">Coarctation of the aorta</span><span class="headingEndMark"> — </span>Classic findings of coarctation of the aorta are systolic hypertension in the right or both upper extremities, diminished or delayed femoral pulses (brachial-femoral delay), and low or unobtainable arterial BP in the lower extremities. (See  <a class="medical medical_review" href="/z/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta", section on 'Blood pressure and pulses'</a>.)</p><p>Patients with uncorrected coarctation of the aorta warrant angioplasty or surgical repair. However, intravenous (IV) antihypertensive therapy may be needed following presentation, especially in older children and adolescents, until definitive treatment can be arranged. The general management of patients with coarctation of the aorta is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5784.html" rel="external">"Management of coarctation of the aorta", section on 'Choice of intervention'</a>.)</p><p class="headingAnchor" id="H3722844527"><span class="h2">Severe pain</span><span class="headingEndMark"> — </span>Children with severe pain should receive systemic analgesia (eg, <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">fentanyl</a> or <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">morphine</a>) with reassessment of BP after pain control.</p><p class="headingAnchor" id="H49359193"><span class="h2">Preeclampsia/eclampsia</span><span class="headingEndMark"> — </span>Delivery of the fetus prevents progression of maternal hypertension and is the primary treatment for preeclampsia. Severe preeclampsia dictates delivery if the pregnancy is beyond 32 weeks gestation. The intrapartum and postpartum management of preeclampsia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p>Women who have severe preeclampsia at less than 32 weeks require management at a tertiary care obstetrical center, which may include antihypertensive therapy. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>.)</p><p class="headingAnchor" id="H2273348897"><span class="h2">Conditions with sympathetic overactivity</span><span class="headingEndMark"> — </span>Patients whose acute severe hypertension arises from sympathetic overactivity warrant modification of treatment depending upon the underlying cause:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cocaine, amphetamine, or other sympathomimetic medication overdose</strong> – In patients presenting with a sympathomimetic overdose, hypertension is frequently transient, and many patients need no specific treatment. Benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/z/d/drug information/12565.html" rel="external">lorazepam</a> or <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a>) are often effective in treating hypertension and agitation. <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">Labetalol</a> and other beta-adrenergic antagonists should be avoided because of the risk of causing unopposed alpha-adrenergic effects, which may exacerbate hypertension and lead to other cardiovascular complications. Rapid-acting IV medications with a short duration of effect such as <a class="drug drug_pediatric" data-topicid="12700" href="/z/d/drug information/12700.html" rel="external">phentolamine</a>, sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>, or <a class="drug drug_pediatric" data-topicid="12646" href="/z/d/drug information/12646.html" rel="external">nitroglycerin</a> are preferred. (See  <a class="medical medical_review" href="/z/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Approach to management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pheochromocytomas and paragangliomas</strong> – Patients who present acutely with severe hypertension from a pheochromocytoma or paraganglioma can be managed in the short term with any of the IV agents discussed above. Once BP has been stabilized, specific therapy with an alpha-blocking agent should be initiated pending surgical resection. (See  <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">"Pheochromocytoma and paraganglioma in children", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">"Pheochromocytoma and paraganglioma in children", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jellyfish sting (Irukandji syndrome)</strong> – Children stung by box jellyfish, which are capable of causing severe pain and hypertension (Irukandji syndrome) and are typically located in the Northern territories of Australia and the Indo-Pacific, require specific treatment of the sting site to inactivate nematocysts and parenteral pain medication. Those with persistent hypertension may also need IV infusions of <a class="drug drug_pediatric" data-topicid="12700" href="/z/d/drug information/12700.html" rel="external">phentolamine</a>, sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>, or <a class="drug drug_pediatric" data-topicid="12646" href="/z/d/drug information/12646.html" rel="external">nitroglycerin</a>. (See  <a class="medical medical_review" href="/z/d/html/2752.html" rel="external">"Jellyfish stings", section on 'Irukandji syndrome (generalized pain and severe hypertension)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scorpion sting</strong> – Children with severe hypertension following a scorpion sting warrant pain control, treatment of hypertension, and, for many scorpion species, antivenom. (See  <a class="medical medical_review" href="/z/d/html/13897.html" rel="external">"Scorpion envenomation causing autonomic dysfunction (North Africa, Middle East, Asia, South America, and the Republic of Trinidad and Tobago)", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H791565427"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/135016.html" rel="external">"Society guideline links: Hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever possible, an experienced clinician such as a pediatric nephrologist or intensivist should guide therapy of pediatric hypertensive emergencies once emergency stabilization is accomplished. Knowledge of the most prevalent etiologies by age group also helps guide medication decisions  (<a class="graphic graphic_table graphicRef73225" href="/z/d/graphic/73225.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Etiology of hypertensive emergency'</a> and <a class="local">'Conditions that alter initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An acute severe elevation in blood pressure (BP) <strong>with</strong> severe, life-threatening symptoms and/or evidence of acute end-organ damage (eg, hypertensive encephalopathy, heart failure, or renal injury) establishes the presence of a hypertensive emergency. Clinicians should be most concerned about target-organ complications in patients with acute development of BP values &gt;30 mmHg above the 95<sup>th</sup> percentile for age, sex, and height  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/z/d/graphic/62371.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">table 3</a>). The absolute level of BP elevation is less important than whether symptoms or evidence of target-organ damage are present. Hypertensive emergencies warrant initial management as described in the algorithm  (<a class="graphic graphic_algorithm graphicRef119591" href="/z/d/graphic/119591.html" rel="external">algorithm 1</a>). (See <a class="local">'Definition'</a> above and <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to antihypertensive treatment, great care must be taken to identify conditions (eg, acute intracranial injury, intracranial mass lesion, uncorrected coarctation of the aorta, or sympathetic overactivity) for which antihypertensive treatment is contraindicated or may need modification in children with severe BP elevation. (See <a class="local">'Conditions that alter initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with hypertensive emergencies without conditions that alter initial treatment, we suggest emergency administration of intravenous (IV) <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> rather than IV <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or sodium <a class="drug drug_pediatric" data-topicid="12648" href="/z/d/drug information/12648.html" rel="external">nitroprusside</a>  (<a class="graphic graphic_table graphicRef80380" href="/z/d/graphic/80380.html" rel="external">table 6</a>) to lower systolic BP in a controlled fashion by no more than 25 percent of the difference between the current systolic BP and the goal systolic BP over the first eight hours of treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial treatment'</a> above and <a class="local">'Conditions that alter initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> is the preferred medication for the treatment of severe symptomatic hypertension in infants younger than one year of age and children with potential contraindications to <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> (eg, patients with asthma or heart failure). (See <a class="local">'Blood pressure goal'</a> above and <a class="local">'Initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to antihypertensive therapy, patients with underlying chronic kidney disease and volume overload or heart failure and pulmonary edema may also warrant diuretic therapy (eg, IV <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a> or <a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">bumetanide</a>) as part of the approach to their hypertension, but diuretics should never be used alone in such patients. (See <a class="local">'Initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If initial therapy with continuous IV infusion of <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> fails to reduce the BP within 30 minutes, therapy is escalated to continuous infusions of <strong>both</strong> labetalol (if not contraindicated) and nicardipine. (See <a class="local">'Failure to respond to initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An acute severe elevation in BP <strong>without</strong> severe, life-threatening symptoms and evidence of acute end-organ damage describes a hypertensive urgency. A child with a hypertensive urgency warrants a prompt evaluation  (<a class="graphic graphic_algorithm graphicRef119592" href="/z/d/graphic/119592.html" rel="external">algorithm 2</a>). (See <a class="local">'Hypertensive urgency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment goal for children with hypertensive urgencies depends upon the clinical situation. The ultimate goal would be a BP &lt;90<sup>th</sup> percentile for age, sex, and height in children &lt;13 years of age or &lt;130/80 in adolescents ≥13 years of age. (See <a class="local">'Hypertensive urgency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with hypertensive urgencies who have a rapid rise in mean arterial BP associated with an acute condition (eg, acute glomerulonephritis), we suggest IV bolus doses of <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> (preferred) or, for infants younger than one year of age or for children with contraindications to labetalol, IV bolus doses of <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a> to lower BP over several hours (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hypertensive urgency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with chronic hypertension due to a known condition (eg, chronic kidney disease) in which BP has increased gradually over time, we suggest oral <a class="drug drug_pediatric" data-topicid="12890" href="/z/d/drug information/12890.html" rel="external">isradipine</a> or, for older children and adolescents, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> to lower BP over several days  (<a class="graphic graphic_table graphicRef57259" href="/z/d/graphic/57259.html" rel="external">table 7</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If the patient cannot take oral medications, then bolus doses of IV medications (<a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">labetalol</a> [preferred], or, for infants younger than one year of age or for children with asthma, bolus IV doses of <a class="drug drug_pediatric" data-topicid="13356" href="/z/d/drug information/13356.html" rel="external">hydralazine</a> or <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">nicardipine</a>) should be given to slowly lower the BP. (See <a class="local">'Hypertensive urgency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once initial control of severe hypertension is achieved, plans should be made for further diagnostic evaluation and correction of any identifiable underlying cause in consultation with the appropriate pediatric subspecialist. (See <a class="local">'Further management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24:1101.</a></li><li><a class="nounderline abstract_t">Seeman T, Hamdani G, Mitsnefes M. Hypertensive crisis in children and adolescents. Pediatr Nephrol 2019; 34:2523.</a></li><li><a class="nounderline abstract_t">Yang WC, Zhao LL, Chen CY, et al. First-attack pediatric hypertensive crisis presenting to the pediatric emergency department. BMC Pediatr 2012; 12:200.</a></li><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.</a></li><li><a class="nounderline abstract_t">Flanigan JS, Vitberg D. Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med Clin North Am 2006; 90:439.</a></li><li><a class="nounderline abstract_t">Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.</a></li><li><a class="nounderline abstract_t">Constantine E, Linakis J. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care 2005; 21:391.</a></li><li><a class="nounderline abstract_t">Fenves AZ, Ram CV. Drug treatment of hypertensive urgencies and emergencies. Semin Nephrol 2005; 25:272.</a></li><li><a class="nounderline abstract_t">Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care 2003; 7:374.</a></li><li><a class="nounderline abstract_t">National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.</a></li><li><a class="nounderline abstract_t">Deal JE, Barratt TM, Dillon MJ. Management of hypertensive emergencies. Arch Dis Child 1992; 67:1089.</a></li><li><a class="nounderline abstract_t">Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 2011; 12:28.</a></li><li><a class="nounderline abstract_t">Lad S, Patil M, Jayashree M, et al. Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children. Indian J Pediatr 2022; 89:7.</a></li><li><a class="nounderline abstract_t">Flynn JT, Bradford MC, Harvey EM. Intravenous Hydralazine in Hospitalized Children and Adolescents with Hypertension. J Pediatr 2016; 168:88.</a></li><li><a class="nounderline abstract_t">Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131:1949.</a></li><li><a class="nounderline abstract_t">Hammer GB, Lewandowski A, Drover DR, et al. Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med 2015; 16:397.</a></li><li><a class="nounderline abstract_t">Koyama K, Yoshida A, Takeda A, et al. Abnormal cyanide metabolism in uraemic patients. Nephrol Dial Transplant 1997; 12:1622.</a></li><li><a class="nounderline abstract_t">Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs 2014; 74:1947.</a></li><li><a class="nounderline abstract_t">Towe E, Tobias JD. Preliminary experience with clevidipine in the pediatric population. J Intensive Care Med 2010; 25:349.</a></li><li><a class="nounderline abstract_t">Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9:399.</a></li><li><a class="nounderline abstract_t">Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15:302.</a></li><li><a class="nounderline abstract_t">Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens (Greenwich) 2010; 12:850.</a></li><li><a class="nounderline abstract_t">Strife CF, Quinlan M, Waldo FB, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986; 78:861.</a></li><li><a class="nounderline abstract_t">Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2003; 2:133.</a></li></ol></div><div id="topicVersionRevision">Topic 6468 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18839219" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Severe hypertension in children and adolescents: pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30276533" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypertensive crisis in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23272766" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : First-attack pediatric hypertensive crisis presenting to the pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473099" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972386" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942520" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The assessment and management of hypertensive emergencies and urgencies in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202700" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drug treatment of hypertensive urgencies and emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12974970" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical review: the management of hypertensive crises.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286277" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1417052" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495503" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33893609" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340877" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous Hydralazine in Hospitalized Children and Adolescents with Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565029" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertensive crises: challenges and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715047" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269639" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Abnormal cyanide metabolism in uraemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25312594" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837631" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Preliminary experience with clevidipine in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485976" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Centrally acting antihypertensive agents: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149130" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054771" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Isradipine for treatment of acute hypertension in hospitalized children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3763300" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Minoxidil for control of acute blood pressure elevation in chronically hypertensive children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904113" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety of short-acting nifedipine in children with severe hypertension.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
